Upcoming events – Reneuron’s conference data and Provention takes on Crohn’s
Reneuron is set to release further data with its hRPC stem cell therapy in retinitis pigmentosa, while Provention Bio aims to target Crohn’s early with PRV-6527.
Reneuron eyes a partner with new stem cell data
Promising retinitis pigmentosa results have given Reneuron a boost, but the company still faces a pivotal trial.
Sanbio brings its Japanese retail fans down to earth
The heavily promoted company’s cell therapy fails a key study in ischaemic stroke.
Deal hopes revive Reneuron
After years in the wilderness, the UK cell therapy specialist Reneuron could be about to seal a deal with a big US player.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.